ENHANCED SUSCEPTIBILITY OF ESCHERICHIA COLI, STAPHYLOCOCCUS AUREUS AND STREPTOCOCCUS PYOGENES TO FLUOROQUINOLONES IN THE PRESENCE OF PROCHLORPERAZINE
Uzma Saleem, Muhammad Hidayat Rasool, Bashir Ahmad, Waqas Sadiq, Saeed Mahmood, Muhammad Saleem1, Alia Erum
1. College of Pharmacy, Govt. College University, Faisalabad, Pakistan 2. University College of Pharmacy, University of the Punjab, Lahore, Pakistan 3. Lahore General Hospital, Lahore, Pakistan 4. Faculty of Pharmacy, University of Sargodha, Sargodha, Pakistan.
Keywords: Enhanced susceptibility; prochlorperazine; fluoroquinolones; Escherichia coli; Staphylococcus aureus; Streptococcus pyogenes
Abstract

Combating the problem of microbial resistance is one of the major challenges the medical sciences facing today. Inhibition of resistance mechanism in bacteria seems much better approach than developing new antibiotics only. The present study was aimed to investigate the effect of different concentrations of prochlorperazine in increasing the effectiveness of fluoroquinolones against Escherichia coli, Staphylococcus aureus and Streptococcus pyogenes. The bacteria were isolated from indigenous sources and identified through cultural characteristics, Grams’ staining and biochemical tests. The master suspensions were subjected to viable count and inoculated at the rate of 106 CFU/ml of the media for antimicrobial sensitivity testing. The four fluoroquinolones i.e. ciprofloxacin, levofloxacin, pefloxacin and norfloxacin were first applied to bacterial cultures alone and then in combination with four different concentrations (16µg/ml, 32µg/ml, 64µg/ml and 128µg/ml) of prochlorperazine and inhibition of growth was recorded in terms of diameter of zones of inhibition. A linear relationship was found between the increase in concentration of prochlorperazine and diameter of zones of inhibition against all the fluoroquinolones. The diameter of zones of inhibition were significantly (p<0.05) greater with 128µg/ml of prochlorperazine in combination with all the four fluoroquinolones against Staphylococcus aureus and Streptococcus pyogenes. In contrast E. coli showed significant susceptibility (p<0.05) only to ciprofloxacin and norfloxacin in the presence of prochlorperazine. It was concluded that prochlorperazine is capable of increasing the susceptibility of Staphylococcus aureus, Streptococcus pyogenes and E coli when used in combination with different fluoroquinolones. This approach of hindering the resistance mechanism of bacteria with non-antibiotics can shift many of the resistant strains of bacteria to susceptible.

Article Information

Identifiers and Pagination:
Year:2010
Volume:2
First Page:140
Last Page:146
Publisher Id:JAppPharm (2010 ). 2. 140-146
Article History:
Received:August 13, 2010
Accepted:November 11, 2010
Collection year:2010
First Published:November 21, 2010


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/